Diabetes – Glucagon-Like Peptide-1 Agonists Prior Authorization Policy - (CNF360)
Cigna prior authorization policy for specified GLP-1 receptor agonists and the GLP-1/GIP agonist for treatment of type 2 diabetes, defining FDA-approved indications covered, age-based approval criteria, and exclusions (not medically necessary uses). Applies to prescription benefit coverage and automation rules noted.
Selected revisions 01/07/2026 and 05/06/2026 updated agent age approvals and added Ozempic tablets to the policy.
Liraglutide (authorized generic to Victoza) and exenatide (generic to Byetta) were added to automation in prior revisions.
Bydureon and Adlyxin were removed from the policy in prior revision history.
Concomitant use prohibition was added to Conditions Not Covered.
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.